Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia

Journal of Clinical Microbiology

Volumn 47, Issue 8, 2009, Pages 2458-2464

  Tropé, Ameli ^a   Sjøborg, Katrine ^b   Eskild, Anne ^a,c,d   Cuschieri, Kate ^e   Eriksen, Tormod ^f   Thoresen, Steinar ^f   Steinbakk, Martin ^a   Laurak, Vigdis ^a   Jonassen, Christine M ^a   Westerhagen, Unni ^a   Jacobsen, Morten B ^b,d   Lie, Agnes Kathrine ^a,g  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b Oestfold Hospital Trust   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (Norway)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER; VIRUS DNA;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENOTYPE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS STRAIN; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REAGENT KITS, DIAGNOSTIC; RNA, VIRAL; UTERINE NEOPLASMS; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES;

EID: 68549109462     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01863-08     Document Type: Article

References (32)

1. Armed Forces Institute of Pathology. 1992. Tumors of the cervix, vulva and vagina, p. 37-128. Armed Forces Institute of Pathology, Washington, DC.
2. Bulkmans, N. W., J. Berkhof, L. Rozendaal, F. J. van Kemenade, A. J. Boeke, S. Bulk, F. J. Voorhorst, R. H. Verheijen, K. van Groningen, M. E. Boon, W. Ruitinga, M. van Ballegooijen, P. J. Snijders, and C. J. Meijer. 2007. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370:1764-1772.
3. Bulkmans, N. W. J., L. Rozendaal, P. J. F. Snijders, F. J. Voorhorst, A. J. P. Boeke, G. R. J. Zandwijken, F. J. van Kemenade, R. H. M. Verheijen, K. V. Groningen, M. E. Boon, H. J. F. Keuning, B. M. Van, A. J. C. Van Den Brule, and C. J. L. M. Meijer. 2004. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int. J. Cancer 110:94-101.
4. Castle, P. E., J. Dockter, C. Giachetti, F. A. R. Garcia, M. K. McCormick, A. L. Mitchell, E. B. Holladay, and D. P. Kolk. 2007. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin. Cancer Res. 13:2599-2605.
5. Cuzick, J., C. Clavel, K.-U. Petry, C. J. L. M. Meijer, H. Hoyer, S. Ratnam, A. Szarewski, P. Birembaut, S. Kulasingam, P. Sasieni, and T. Iftner. 2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119:1095-1101.
6. Cuzick, J., A. Szarewski, H. Cubie, G. Hulman, H. Kitchener, D. Luesley, E. McGoogan, U. Menon, G. Terry, R. Edwards, C. Brooks, M. Desai, C. Gie, L. Ho, I. Jacobs, C. Pickles, and P. Sasieni. 2003. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362:1871-1876.
7. Doorbar, J. 2006. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. 110:525-541.
8. International Agency for Cancer Research. 2005. Handbook of cancer prevention: cervix cancer screening, vol. 10. International Agency for Research on Cancer Press, Lyon, France.
9. Kitchener, H. C., M. Almonte, P. Wheeler, M. Desai, C. Gilham, A. Bailey, A. Sargent, J. Peto, and the ARTISTIC Trial Study Group. 2006. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br. J. Cancer 95:56-61.
10. Kjaer, S. K., G. Breugelmans, C. Munk, J. Junge, M. Watson, and T. Iftner. 2008. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int. J. Cancer 123:1864-1870.
11. Kraus, I., T. Molden, R. Holm, A. K. Lie, F. Karlsen, G. B. Kristensen, and H. Skomedal. 2006. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J. Clin. Microbiol. 44:1310-1317.
12. Kulasingam, S. L., J. P. Hughes, N. B. Kiviat, C. Mao, N. S. Weiss, J. M. Kuypers, and L. A. Koutsky. 2002. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 288:1749-1757.
13. Lie, A. K., and G. Kristensen. 2008. Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma. Expert Rev. Mol. Diagn. 8:405-415.
14. Lie, A. K., B. Risberg, B. Borge, B. Sandstad, J. Delabie, R. Rimala, M. Onsrud, and S. Thoresen. 2005. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol. Oncol. 97: 908-915.
15. McCredie, M. R., K. J. Sharples, C. Paul, J. Baranyai, G. Medley, R. W. Jones, and D. C. Skegg. 2008. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 9:425-434.
16. McIndoe, W. A., M. R. McLean, R. W. Jones, and P. R. Mullins. 1984. The invasive potential of carcinoma in situ of the cervix. Obstetr. Gynecol. 64: 451-458.
17. Molden, T., I. Kraus, F. Karlsen, H. Skomedal, J. F. Nygard, and B. Hagmar. 2005. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol. Biomarkers Prev. 14:367-372.
18. Molden, T., J. F. Nygard, I. Kraus, F. Karlsen, M. Nygard, G. B. Skare, H. Skomedal, S. O. Thoresen, and B. Hagmar. 2005. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-Proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int. J. Cancer 114:973-976.
19. Moscicki, A.-B., M. Schiffman, S. Kjaer, and L. L. Villa. 2006. Updating the natural history of HPV and anogenital cancer. Vaccine 24:S42-S51.
20. Munoz, N., F. X. Bosch, X. Castellsague, M. Diaz, S. de Sanjose, D. Hammouda, K. V. Shah, and C. J. Meijer. 2004. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111:278-285.
21. Munoz, N., X. Castellsague, A. B. de Gonzalez, and L. Gissmann. 2006. HPV in the etiology of human cancer. Vaccine 24:S1-S10.
22. Ostor, A. G. 1993. Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 12:186-192.
23. Petry, K.-U., S. Menton, M. Menton, F. Van Loenen-Frosch, G. H. De Carvalho, B. Holz, B. Schopp, S. Garbrecht-Buettner, P. Davies, G. Boehmer, A. E. Van Den, and T. Iftner. 2003. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br. J. Cancer 88:1570-1577.
24. Ratnam, S., E. L. Franco, and A. Ferenczy. 2000. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol. Biomarkers Prev. 9:945-951.
25. Schiffman, M., M. J. Khan, D. Solomon, R. Herrero, S. Wacholder, A. Hildesheim, A. C. Rodriguez, M. C. Bratti, C. M. Wheeler, R. D. Burk, PEG Group, and the ALTS Group. 2005. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J. Natl. Cancer Inst. 97:147-150.
26. Smith, J. S., L. Lindsay, B. Hoots, J. Keys, S. Frasceschi, R. Winer, and G. M. Clifford. 2007. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121:621-632.
27. Solomon, D., D. Davey, R. Kurman, A. Moriarty, D. O'Connor, M. Prey, S. Raab, M. Sherman, D. Wilbur, J. T. Wright, N. Young, W. Kinney, A. Meisels, E. Cibas, G. Gill, M. McLachlin, E. Sheets, T. Somrak, R. Zuna, T. Wright, R. DeMay, R. M. Gatscha, L. Howell, R. Luff, V. Schneider, L. Twiggs, M. Facik, A. Reith, M. Robinowitz, M. Rubin, S. Zaleski, M. Austin, L. Flowers, B. Holladay, D. McCoy, P. Krieger, G. Medley, J. Nash, M. Sidoti, and L. Kil. 2002. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 287:2114-2119.
28. Stevens, M. P., S. M. Garland, E. Rudland, J. Tan, M. A. Quinn, and S. N. Tabrizi. 2007. Comparison of the Digene Hybrid Capture 2 assay and Roche Amplicor and Linear Array human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J. Clin. Microbiol. 45:2130-2137.
29. Szarewski, A., L. Ambroisine, L. Cadman, J. Austin, L. Ho, G. Terry, S. Liddle, R. Dina, J. McCarthy, H. Buckley, C. Bergeron, P. Soutter, D. Lyons, and J. Cuzick. 2008. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol. Biomarkers Prev. 17:3033-3042.
30. Walboomers, J. M., M. V. Jacobs, M. M. Manos, F. X. Bosch, J. A. Kummer, K. V. Shah, P. J. Snijders, J. Peto, C. J. Meijer, and N. Munoz. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19.
31. Woodman, C. B., S. I. Collins, and L. S. Young. 2007. The natural history of cervical HPV infection: unresolved issues. Nat. Rev. 7:11-22.
32. Zur, H. H. 2002. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2:342-350.